Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.
Identifieur interne : 001A43 ( PubMed/Corpus ); précédent : 001A42; suivant : 001A44Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.
Auteurs : Lynn Million ; Esther J. Yi ; Frank Wu ; Rie Von Eyben ; Belinda A. Campbell ; Bouthaina Dabaja ; Richard W. Tsang ; Andrea Ng ; Lynn D. Wilson ; Umberto Ricardi ; Youlia Kirova ; Richard T. HoppeSource :
- International journal of radiation oncology, biology, physics [ 1879-355X ] ; 2016.
English descriptors
- KwdEn :
- Adult, Aged, Dose Fractionation, Evidence-Based Medicine, Female, Humans, Internationality, Lymphoma, Large-Cell, Anaplastic (diagnosis), Lymphoma, Large-Cell, Anaplastic (radiotherapy), Male, Middle Aged, Neoplasm Recurrence, Local (diagnosis), Neoplasm Recurrence, Local (prevention & control), Radiotherapy, Conformal (methods), Retrospective Studies, Skin Neoplasms (diagnosis), Skin Neoplasms (radiotherapy), Survival Rate, Treatment Outcome.
- MESH :
- diagnosis : Lymphoma, Large-Cell, Anaplastic, Neoplasm Recurrence, Local, Skin Neoplasms.
- methods : Radiotherapy, Conformal.
- prevention & control : Neoplasm Recurrence, Local.
- radiotherapy : Lymphoma, Large-Cell, Anaplastic, Skin Neoplasms.
- Adult, Aged, Dose Fractionation, Evidence-Based Medicine, Female, Humans, Internationality, Male, Middle Aged, Retrospective Studies, Survival Rate, Treatment Outcome.
Abstract
To collect response rates of primary cutaneous anaplastic large cell lymphoma, a rare cutaneous T-cell lymphoma, to radiation therapy (RT), and to determine potential prognostic factors predictive of outcome.
DOI: 10.1016/j.ijrobp.2016.03.023
PubMed: 27315663
Links to Exploration step
pubmed:27315663Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.</title><author><name sortKey="Million, Lynn" sort="Million, Lynn" uniqKey="Million L" first="Lynn" last="Million">Lynn Million</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California. Electronic address: lmillion@stanford.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Yi, Esther J" sort="Yi, Esther J" uniqKey="Yi E" first="Esther J" last="Yi">Esther J. Yi</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Frank" sort="Wu, Frank" uniqKey="Wu F" first="Frank" last="Wu">Frank Wu</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California.</nlm:affiliation></affiliation></author><author><name sortKey="Von Eyben, Rie" sort="Von Eyben, Rie" uniqKey="Von Eyben R" first="Rie" last="Von Eyben">Rie Von Eyben</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California.</nlm:affiliation></affiliation></author><author><name sortKey="Campbell, Belinda A" sort="Campbell, Belinda A" uniqKey="Campbell B" first="Belinda A" last="Campbell">Belinda A. Campbell</name><affiliation><nlm:affiliation>Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Dabaja, Bouthaina" sort="Dabaja, Bouthaina" uniqKey="Dabaja B" first="Bouthaina" last="Dabaja">Bouthaina Dabaja</name><affiliation><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation></affiliation></author><author><name sortKey="Tsang, Richard W" sort="Tsang, Richard W" uniqKey="Tsang R" first="Richard W" last="Tsang">Richard W. Tsang</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ng, Andrea" sort="Ng, Andrea" uniqKey="Ng A" first="Andrea" last="Ng">Andrea Ng</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Wilson, Lynn D" sort="Wilson, Lynn D" uniqKey="Wilson L" first="Lynn D" last="Wilson">Lynn D. Wilson</name><affiliation><nlm:affiliation>Department of Therapeutic Radiology/Radiation Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Ricardi, Umberto" sort="Ricardi, Umberto" uniqKey="Ricardi U" first="Umberto" last="Ricardi">Umberto Ricardi</name><affiliation><nlm:affiliation>Department of Oncology, University of Turin, Turin, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Kirova, Youlia" sort="Kirova, Youlia" uniqKey="Kirova Y" first="Youlia" last="Kirova">Youlia Kirova</name><affiliation><nlm:affiliation>Institut Curie, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hoppe, Richard T" sort="Hoppe, Richard T" uniqKey="Hoppe R" first="Richard T" last="Hoppe">Richard T. Hoppe</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27315663</idno><idno type="pmid">27315663</idno><idno type="doi">10.1016/j.ijrobp.2016.03.023</idno><idno type="wicri:Area/PubMed/Corpus">001A43</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A43</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.</title><author><name sortKey="Million, Lynn" sort="Million, Lynn" uniqKey="Million L" first="Lynn" last="Million">Lynn Million</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California. Electronic address: lmillion@stanford.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Yi, Esther J" sort="Yi, Esther J" uniqKey="Yi E" first="Esther J" last="Yi">Esther J. Yi</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Frank" sort="Wu, Frank" uniqKey="Wu F" first="Frank" last="Wu">Frank Wu</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California.</nlm:affiliation></affiliation></author><author><name sortKey="Von Eyben, Rie" sort="Von Eyben, Rie" uniqKey="Von Eyben R" first="Rie" last="Von Eyben">Rie Von Eyben</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California.</nlm:affiliation></affiliation></author><author><name sortKey="Campbell, Belinda A" sort="Campbell, Belinda A" uniqKey="Campbell B" first="Belinda A" last="Campbell">Belinda A. Campbell</name><affiliation><nlm:affiliation>Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Dabaja, Bouthaina" sort="Dabaja, Bouthaina" uniqKey="Dabaja B" first="Bouthaina" last="Dabaja">Bouthaina Dabaja</name><affiliation><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation></affiliation></author><author><name sortKey="Tsang, Richard W" sort="Tsang, Richard W" uniqKey="Tsang R" first="Richard W" last="Tsang">Richard W. Tsang</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ng, Andrea" sort="Ng, Andrea" uniqKey="Ng A" first="Andrea" last="Ng">Andrea Ng</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Wilson, Lynn D" sort="Wilson, Lynn D" uniqKey="Wilson L" first="Lynn D" last="Wilson">Lynn D. Wilson</name><affiliation><nlm:affiliation>Department of Therapeutic Radiology/Radiation Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Ricardi, Umberto" sort="Ricardi, Umberto" uniqKey="Ricardi U" first="Umberto" last="Ricardi">Umberto Ricardi</name><affiliation><nlm:affiliation>Department of Oncology, University of Turin, Turin, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Kirova, Youlia" sort="Kirova, Youlia" uniqKey="Kirova Y" first="Youlia" last="Kirova">Youlia Kirova</name><affiliation><nlm:affiliation>Institut Curie, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hoppe, Richard T" sort="Hoppe, Richard T" uniqKey="Hoppe R" first="Richard T" last="Hoppe">Richard T. Hoppe</name><affiliation><nlm:affiliation>Stanford Cancer Institute, Stanford, California.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International journal of radiation oncology, biology, physics</title><idno type="eISSN">1879-355X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose Fractionation</term><term>Evidence-Based Medicine</term><term>Female</term><term>Humans</term><term>Internationality</term><term>Lymphoma, Large-Cell, Anaplastic (diagnosis)</term><term>Lymphoma, Large-Cell, Anaplastic (radiotherapy)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (diagnosis)</term><term>Neoplasm Recurrence, Local (prevention & control)</term><term>Radiotherapy, Conformal (methods)</term><term>Retrospective Studies</term><term>Skin Neoplasms (diagnosis)</term><term>Skin Neoplasms (radiotherapy)</term><term>Survival Rate</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lymphoma, Large-Cell, Anaplastic</term><term>Neoplasm Recurrence, Local</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radiotherapy, Conformal</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Lymphoma, Large-Cell, Anaplastic</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose Fractionation</term><term>Evidence-Based Medicine</term><term>Female</term><term>Humans</term><term>Internationality</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Survival Rate</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To collect response rates of primary cutaneous anaplastic large cell lymphoma, a rare cutaneous T-cell lymphoma, to radiation therapy (RT), and to determine potential prognostic factors predictive of outcome.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27315663</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>02</Day></DateCreated><DateCompleted><Year>2017</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-355X</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of radiation oncology, biology, physics</Title><ISOAbbreviation>Int. J. Radiat. Oncol. Biol. Phys.</ISOAbbreviation></Journal><ArticleTitle>Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.</ArticleTitle><Pagination><MedlinePgn>1454-1459</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0360-3016(16)00335-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijrobp.2016.03.023</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To collect response rates of primary cutaneous anaplastic large cell lymphoma, a rare cutaneous T-cell lymphoma, to radiation therapy (RT), and to determine potential prognostic factors predictive of outcome.</AbstractText><AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">The study was a retrospective analysis of patients with primary cutaneous anaplastic large cell lymphoma who received RT as primary therapy or after surgical excision. Data collected include initial stage of disease, RT modality (electron/photon), total dose, fractionation, response to treatment, and local recurrence. Radiation therapy was delivered at 8 participating International Lymphoma Radiation Oncology Group institutions worldwide.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-six patients met the eligibility criteria, and 63 tumors were treated: head and neck (27%), trunk (14%), upper extremities (27%), and lower extremities (32%). Median tumor size was 2.25 cm (range, 0.6-12 cm). T classification included T1, 40 patients (71%); T2, 12 patients (21%); and T3, 4 patients (7%). The median radiation dose was 35 Gy (range, 6-45 Gy). Complete clinical response (CCR) was achieved in 60 of 63 tumors (95%) and partial response in 3 tumors (5%). After CCR, 1 tumor recurred locally (1.7%) after 36 Gy and 7 months after RT. This was the only patient to die of disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Primary cutaneous anaplastic large cell lymphoma is a rare, indolent cutaneous lymphoma with a low death rate. This analysis, which was restricted to patients selected for treatment with radiation, indicates that achieving CCR was independent of radiation dose. Because there were too few failures (<2%) for statistical analysis on dose response, 30 Gy seems to be adequate for local control, and even lower doses may suffice.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Million</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stanford Cancer Institute, Stanford, California. Electronic address: lmillion@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Esther J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Stanford Cancer Institute, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Stanford Cancer Institute, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Von Eyben</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Stanford Cancer Institute, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Belinda A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabaja</LastName><ForeName>Bouthaina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Lynn D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Therapeutic Radiology/Radiation Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricardi</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Oncology, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirova</LastName><ForeName>Youlia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institut Curie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoppe</LastName><ForeName>Richard T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Stanford Cancer Institute, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA124435</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Radiat Oncol Biol Phys</MedlineTA><NlmUniqueID>7603616</NlmUniqueID><ISSNLinking>0360-3016</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Jul 15;110(2):479-84</RefSource><PMID Version="1">17339420</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Oct 13;118(15):4024-35</RefSource><PMID Version="1">21841159</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Dermatol. 2009 Jul;161(1):121-7</RefSource><PMID Version="1">19416236</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 May 15;105(10):3768-85</RefSource><PMID Version="1">15692063</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cutan Pathol. 2013 Feb;40(2):236-47</RefSource><PMID Version="1">23189966</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Mar 20;26(9):1483-8</RefSource><PMID Version="1">18349400</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1542-5</RefSource><PMID Version="1">18037577</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 2003 Dec;49(6):1049-58</RefSource><PMID Version="1">14639383</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Dermatol. 2009 Jun;145(6):667-74</RefSource><PMID Version="1">19528422</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Dtsch Dermatol Ges. 2012 May;10(5):331-9</RefSource><PMID Version="1">22525148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomed Res Int. 2015;2015:629587</RefSource><PMID Version="1">26504818</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2013 Apr;54(4):752-9</RefSource><PMID Version="1">23004352</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):747-53</RefSource><PMID Version="1">22818412</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019583" MajorTopicYN="N">Dose Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017728" MajorTopicYN="N">Lymphoma, Large-Cell, Anaplastic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020266" MajorTopicYN="N">Radiotherapy, Conformal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27315663</ArticleId><ArticleId IdType="pii">S0360-3016(16)00335-7</ArticleId><ArticleId IdType="doi">10.1016/j.ijrobp.2016.03.023</ArticleId><ArticleId IdType="pmc">PMC5488803</ArticleId><ArticleId IdType="mid">NIHMS858329</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001A43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27315663
|texte= Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27315663" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |